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DObjectives: The present study examined the relationship between hospital and surgeon coronary artery bypass
grafting procedural volume, mortality, morbidity, and National Quality Forum care processes in a university-
based community hospital quality improvement program.
Methods: The study population consisted of 2218 consecutive patients undergoing isolated coronary artery
bypass grafting from 2007 to 2009 in a university-based quality improvement program that emphasizes involve-
ment of all surgeons in the academic quality endeavor. The endpoints included operative mortality, major mor-
bidity, and National Quality Forum-endorsed process measures as defined by the Society of Thoracic Surgeons.
The procedural volume was analyzed as a categorical and continuous variable using general estimating
equations, which accounted for clustering effects and which were adjusted for Society of Thoracic Surgeons
risk scores and the propensity for operation in a low- versus high-volume program.
Results: The annual program volume ranged from 67 to 292 (median, 136; interquartile range, 88–224) and sur-
geon volume from 1 to 124 (median, 58; interquartile range, 30–89). The mortality rate among the hospitals was
0.47% to 2.23% (0.8% overall), and the observed/expected mortality ranged from 0 to 1.20 (0.41 overall).
When comparing low-volume (<200 cases/year) and high-volume centers, no difference was found in the mor-
tality (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.46–2.54, P¼ .85), morbidity (OR, 1.34; 95% CI,
0.73–2.43), or any of the medication process measures. No differencewas found in mortality (OR, 1.59; 95%CI,
0.81–3.13; P ¼ .18), morbidity (OR, 1.20; 95% CI, 0.86–1.66; P ¼ .28), or medication failure (OR, 0.57, 95%
CI, 0.3–1.10; P¼ .10) between the high- and low-volume surgeons (<87). After adjustment for both the Society
of Thoracic Surgeons risk score and the propensity score, no association was found for either hospital or surgeon
volume with mortality or morbidity. However, a lack of compliance with National Quality Forum measures was
highly predictive of morbidity (OR, 1.51; 95% CI, 1.18–1.93; P ¼ .001), regardless of volume, even after
adjustment for predicted risk.
Conclusions: In the setting of a university-based community hospital quality improvement program, excellent sur-
gical results can consistently be obtained even in relatively low-volume programs. The surgical outcomeswere not
associatedwith programor surgeonvolume, butwere directly correlatedwith the focus on quality asmanifested by
compliancewith evidence-based quality standards.Meaningful university affiliationmight represent a new quality
paradigm for cardiac surgery in the community hospital setting. (J Thorac Cardiovasc Surg 2012;143:287-93)Supplemental material is available online.e Florida Heart Research Institute,a Miami, Fla; and the Departments of
ryb and Biostatistics,c Columbia University, New York, NY.
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The Journal of Thoracic and CaThe evidence supporting a correlation between an increased
case volume and decreased operative mortality for complex
surgical procedures is copious and robust.1-3 In the case of
coronary artery bypass grafting (CABG), the situation
appears to be considerably more complex.4 A review of
the aggregate data clearly seems to indicate that a similar
trend, albeit perhaps less dramatic, exists for CABG surgery,
just as for other complex operations.2,5,6 However, careful
evaluation revealed a much more complicated picture.
Recent analysis of the data from the Society of Thoracic
Surgeons (STS) Adult Cardiac Database demonstrated that
volume, although significantly correlated with mortality,
accounted for only 1% of the composite quality score
variation.7 Moreover, several careful studies have demon-
strated an absence of a correlation between volume andmor-
tality in CABG surgery.8-10 An analysis of the Nationalrdiovascular Surgery c Volume 143, Number 2 287
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HV ¼ high volume
LV ¼ low volume
OR ¼ odds ratio
STS ¼ Society of Thoracic Surgeons
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DInpatient Sample revealed that 85% of ‘‘low-volume’’ (LV)
and 89% of ‘‘medium-volume’’ hospital-years had risk-
standardized mortality rates that were statistically lower or
comparable to those expected, and only 6% of ‘‘high-
volume’’ (HV) hospital-years had outcomes that were statis-
tically better than expected.11 Therefore,manyLVprograms
have excellent results, and some larger programs have less
than average results.12 Thus, volume, although a readily
available and easily trackable parameter, is neither a require-
ment nor a guarantee of quality.
During the past decade, an increase has occurred in car-
diac surgical programs despite a marked decline in CABG
volume.13 Remarkably, however, mortality has continued
to decline.14 Perhaps even more surprising is that this de-
crease in mortality has been achieved in the face of an
increasingly complex, high-risk patient population.15
Clearly, the relation between volume and quality in CABG
surgery is complex at best. We therefore decided to study
the effect of surgical volume on the processes and outcomes
of CABG surgery in a network of LV and medium-volume
community hospital cardiac surgical programs affiliated
with an academic medical center. It is our hypothesis that
a concerted and informed focus on quality is more important
than case volume in determining the outcomes of CABG
surgery.MATERIALS AND METHODS
Study Population
The study populations consisted of all patients who underwent isolated
CABG surgery in any of five cardiac surgery programs affiliated with the
Columbia University HeartSource program from 2007 to 2009. The Co-
lumbia HeartSource project represents the services of a team that includes
senior cardiac surgeons and cardiologists, clinical staff, business managers,
and administrators, all from the Divisions of Cardiothoracic Surgery and
Cardiology of Columbia University Medical Center (available at: http://
www.columbiasurgery.org/cli/heartsrc/). The purpose of the project is to
engage community hospitals in an academically-based endeavor to en-
hance an existing cardiovascular program or to launch one de novo. The
program involves active involvement of the Columbia faculty in quality im-
provement, strategic planning, physician recruitment, regular morbidity/
mortality/quality rounds, external peer review of all deaths and other inter-
esting or significant cases, and the availability of Columbia faculty for real-
time consultation and discussion of challenging cases, academic teaching
rounds, and opportunities for direct intraoperative teaching at both the Co-
lumbia Medical Center campus and the local level. All surgical cases are
prospectively entered into a web-based proprietary STS-compliant288 The Journal of Thoracic and Cardiovascular Surgdatabase that is regularly monitored for timeliness and accuracy. Entry
into the present study included all hospitals in the network that had been
participating in the program for at least a full year before study inception
in 2007, and for at least 2 years of validated data were available. These cri-
teria resulted in the review of five surgical programs from January 1, 2007
to December 31, 2009—one with 2 years of data and the remainder with 3.
A total of 3341 patients had undergone cardiac surgery during the study pe-
riod, of whom 2218 underwent isolated CABG. Because of the complexity
of the potential confounding variables and the need to maintain adequate
study volume, only patients undergoing isolated CABG were included in
the present analysis.
There were several analysis-specific exclusion criteria. First, the
patients with preoperative renal failure were excluded when analyzing
postoperative renal failure. Second, the patients with preoperative cerebro-
vascular accidents were excluded when analyzing stroke. Third, the pa-
tients with previous CABG were excluded when analyzing internal
thoracic artery use. Fourth, the patients who died in the hospital were ex-
cluded when analyzing discharge data. Fifth, the patients who had contra-
indications to any of the perioperative medications were excluded when
analyzing medication compliance. Finally, the patients who died were
excluded when analyzing the quality process measures.
Primary Predictors
The CABG volume was treated as a categorical variable. A hospital for
a particular year was considered LV if it had fewer than 200 CABG cases.
We also considered surgeon volume and hospital quality. The surgeons for
a particular year were regarded as LV if they performed fewer than 59
CABG operations. In terms of quality, each patient received a ‘‘total quality
score,’’ ranging from 0 to 5, depending on the number of National Quality
Forum measures that were achieved. A patient with a score of 5 was
considered as receiving high-quality care from the hospital; otherwise,
the patient received low-quality care.
Study Endpoints
The standard STS definitions were applied to all variables. The relation
between hospital and surgeon CABGvolumewas correlated with those risk
factors that were significant in the STS risk model. The endpoints included
National Quality Forum-endorsed process measures (internal thoracic ar-
tery graft; preoperative b-blockade; and discharge b-blockade, antiplatelet
agents, and lipid drugs), operative mortality (30 days), major morbidity
(stroke, renal failure, reoperation, sternal infection, and prolonged ventila-
tion). All calculations of operative or complication risk were computed
using the STS risk calculator.Statistical Analyses
Marginal logistic regression models based on generalized estimating
equations were performed to examine the crude and adjusted relationships
between CABG outcomes and hospital volume while accounting for corre-
lation among patients within the same hospital. The propensity score
methods were used to achieve a better balance in patient characteristics be-
tween LVand HV hospitals. The patients were separated into quintiles de-
fined by their propensity scores, and the propensity quintile was included in
the model already adjusted for hospital volume and predicted risk score.
Generalized estimating equation methods were also applied to analyses
that examined the effect of surgeon volume on CABG outcomes, account-
ing for correlation among patients treated by the same surgeon. Both crude
and predicted risk score adjusted analyses were performed. Similarly, the
generalized estimating equations approach was used to compare CABG
outcomes between low- and high-quality patients, accounting for within-
hospital associations. As before, crude and predicted risk score adjusted
analyses were performed. A marginal log-linear regression model was fit
to determine the relationship between a discrete quality score (ranging
from 0 to 5) and hospital volume, accounting for hospital cluster. Oddsery c February 2012
TABLE 1. Selected baseline comparisons by hospital volume
Characteristic
Low volume
(n ¼ 787)
High volume
(n ¼ 1431)
P
value
Age (yr) 64.6  10.4 65.9  10.4 .004
Male (n) 593 (75.3) 1063 (74.3) .58
Weight (kg) 88.7  19.7 87.1  18.3 .069
Height (cm) 171.1  10.3 172.5  9.91 .002
Diabetes (n) 329  41.8 490 (34.2) <.001
Ejection fraction (%) 48.9  12.5 52.6  11.5 <.001
Last preoperative creatinine
level (n)
1.2 (0.9) 1.2 (0.9) .22
Chronic lung disease (n) 216 (27.4) 168 (11.7) <.001
Hypertension (n) 645 (82) 1191 (83.2) .45
Peripheral arterial disease (n) 131 (16.6) 165 (11.5) <.001
Cerebrovascular disease (n) 114 (14.5) 160 (11.2) .02
Cardiogenic Shock (n) 5 (0.6) 8 (0.6) .78
Reoperation (n) 17 (2.2) 32 (2.2) .91
Nonelective status (n) 504 (64) 666 (46.5) <.001
Data in parentheses are percentages.
TABLE 2. Unadjusted odds ratios of outcome and quality measures
for patients in low- and high-volume hospitals
Variable OR (95% CI) P Value
Domains
Mortality 1.08 (0.46–2.54) .85
Morbidity 1.34 (0.73–2.43) .34
ITA failure 1.92 (1.15–3.19) .01
Medication failure 0.57 (0.25–1.30) .18
Morbidity
Stroke 0.32 (0.21–0.49) <.001
Reoperation 1.01 (0.51–2.00) .98
Sternal infection 4.13 (2.16–7.86) <.001
Prolonged ventilation 1.75 (1.01–3.03) .048
Renal failure 1.27 (0.51–3.17) .60
Medication failure
Preoperative b-blockade 0.54 (0.19–1.53) .25
D/C b-blockade 0.55 (0.18–1.68) .29
Antiplatelet agents 0.80 (0.48–1.33) .39
Lipid drugs 0.60 (0.24–1.47) .26
OR, Odds ratio; CI, confidence interval; ITA, internal thoracic artery; D/C, hospital
discharge.
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Dratios (ORs) and 95% confidence intervals (CIs) were reported for all anal-
yses. All analyses were performed using SAS, version 9.2 (SAS Institute,
Cary, NC). P<.05 was considered significant.
Missing Data
No data were missing for the CABG outcomes or the primary predictors
of interest. However, missing data were encountered when creating the pro-
pensity score model, which incorporated variables in the STS 2008 Risk
Model that had a role in all the endpoints measured. We followed the im-
putation guidelines for continuous and categorical variables provided in the
STS report (period ending December 31, 2009).
Institutional Review Board
Institutional review board approval was obtained from the Columbia
University institutional board and appropriate review boards at each of
the hospitals involved in the study.RESULTS
The hospital volume/year ranged from 67 to 292 (me-
dian, 136; interquartile range, 88–224), with three hospitals
consistently performing fewer than 200 cases/year (range,
67–140), hereafter referred to as LV hospitals, and two
consistently performing more than 200 cases/year (range,
201–292), hereafter referred to as HV hospitals. The distri-
bution of baseline characteristics between the LV and HV
programs is listed in Table 1. Diabetes, reduced ejection
fraction, chronic obstructive lung disease, peripheral arte-
rial disease, cerebrovascular disease, and urgent or emer-
gent status were all statistically more prevalent among the
LV than the HV patients. Off-pump surgery was much
more common in one of the two HV hospitals. Because
this reflected a particular surgeon preference rather than
a volume-related phenomenon, the effect of the off-pump
versus on-pump preference could not be evaluated in the
present study. Of those patients who underwent on-pump
CABG, the bypass time was longer in the LV (117  4.4The Journal of Thoracic and Caminutes, least squares mean  standard error) than in the
HV (96.4  5.4) programs (P ¼ .033), but the crossclamp
time (78.1  2.7 vs 72.7  3.4 minutes; P ¼ .22) and num-
ber of distal grafts (3.1 0.13 vs 3.5 0.16; P¼ .075) was
similar. The mortality rate among the hospitals ranged from
0% to 2.23% (0.8% overall), and the annual observed/ex-
pected mortality ranged from 0 to 1.20 (0.41 overall). The
total morbidity rate (sum of all five complications) ranged
from 7.7% to 17.1% (11.7% overall). Despite the some-
what different risk profile of the two groups, no difference
was found in mortality or overall morbidity between the
LVand HV groups (Table 2). A failure to use an internal tho-
racic artery graft was more common in the LV programs
(OR, 1.92; 95% CI, 1.15–3.19; P ¼ .01), but no difference
was found in the failure to meet any of the National Quality
Forummedication parameters, either individually or collec-
tively. Stroke appeared to be more common in the HV
programs with a LV/HV OR of 0.32 (95% CI, 0.21–0.49;
P<.001), and sternal infection was more common in the
LV programs (OR, 4.13; 95% CI, 2.16–7.86; P<.001), al-
though the latter result must be interpreted with some cau-
tion, because only six sternal wound infections developed
during the entire study period. When each of those out-
comes for which an STS risk score exists were compared
after adjusting for predicted risk, stroke was still more com-
mon among the HV patients and sternal infection was still
more common among the LV patients (Table 3). We further
corrected for patient propensity to be treated at a LV versus
HV program using propensity quintiles, while adjusting
for predicted risk, and found that stroke was still more com-
mon amongst the HV patients and the incidence of sternal
infection was no longer significantly different (Table E1).rdiovascular Surgery c Volume 143, Number 2 289
TABLE 3. Odds ratios for outcome measures in patients of low- and
high-volume hospitals adjusted for predicted risk
Variable OR (95% CI) P Value
Mortality 1.09 (0.49–2.43) .83
Mortality or morbidity 1.18 (0.47–2.98) .72
Stroke 0.33 (0.22–0.50) <.001
Reoperation 1.01 (0.50–2.04) .97
Sternal infection 3.51 (1.95–6.31) <.001
Prolonged ventilation 1.26 (0.54–2.92) .59
Renal failure 1.06 (0.31–3.57) .93
OR, Odds ratio; CI, confidence interval.
TABLE 4. Odds ratios of outcome measures for patients with low-
versus high-volume surgeons
Variable OR (95% CI) P Value
Domains
Mortality 1.59 (0.81–3.13) .18
Morbidity 1.20 (0.86–1.66) .28
ITA failure 1.80 (0.65–4.96) .26
Medication failure 0.57 (0.30–1.10) .10
Morbidity
Stroke 0.43 (0.14–1.34) .15
Reoperation 1.12 (0.58–2.16) .74
Sternal infection 0.66 (0.11–3.86) .64
Prolonged ventilation 1.26 (0.83–1.91) .28
Renal failure 0.91 (0.47–1.77) .78
Medication failure
Preoperative b-blockade 0.64 (0.43–0.94) .02
D/C b-blockade 0.70 (0.46–1.08) .10
Antiplatelet agents 0.59 (0.25–1.41) .24
Lipid drugs 0.81 (0.24–2.68) .73
OR, Odds ratio; CI, confidence interval; ITA, internal thoracic artery; D/C, hospital
discharge.
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than hospital volume. Surgeon volume/year ranged from 1
to 124 (median, 58.5; interquartile range, 59). When evalu-
ating the outcomes for patients who had a LV (<59 cases/yr)
versus a HV (59 cases/yr) surgeon, we found no differ-
ence in mortality, morbidity, or any process measure, with
the exception that the patients of a LV surgeon were less
likely to receive preoperative b-blockade (OR, 0.64; 95%
CI, 0.43–0.94; P ¼ .02; Table 4). When adjusted for pre-
dicted risk, no difference was seen in the incidence of mor-
tality, overall, or any specific morbidity between patients of
LV versus HV surgeons (Table E2).
Because compliance with process measures might repre-
sent a focus on quality, we assigned to each patient a simple
‘‘quality score’’ (range, 0–5) according to how many of the
National Quality Forum measures were achieved for that
given patient. Because the patient required successful dis-
charge from the hospital for three of the five measures, all
those patients who died in the hospital were excluded
from this analysis. The vast majority of patients (1617/
2195, 73.7%) had a 5/5 score. A marginal log-linear regres-
sion analysis, accounting for within-hospital associations
analyzing quality score as the outcome and hospital volume,
failed to show an association (P ¼ .27). However, when the
quality score (5 vs <5) was correlated with morbidity,
a statistically significant association was found with overall
morbidity and with each individual complication, with the
exception of sternal infection (Table 5). This association
between process and outcome remained highly significant
after adjusting for predicted risk.DISCUSSION
Although evidence of an association between volume and
mortality for CABG has been shown, the nature of this
relationship is not clear. Evidence seems to contradict
both the ‘‘practice makes perfect’’ intuitive approach,
with smaller programs not uncommonly outperforming
larger ones,11,12 and the ‘‘selective referral’’ phenomenon,
with the higher volume hospitals and surgeons in New
York State caring for the higher risk patients.5 With volume
having so little predictive value in determining the out-
comes of CABG patients,10 there clearly must be other290 The Journal of Thoracic and Cardiovascular Surgmore compelling factors. Fortunately, as a profession, the
investment that cardiac surgeons have made in developing
robust registries with clinically meaningful risk adjustment
permits measurement of outcomes directly rather than
through surrogate markers. From the standpoint of public
policy, this information facilitates knowledgeable decisions
using actual, rather than surrogate, benchmarks. For the cli-
nician, the challenge is to learn which factors appear to
drive quality outcomes, and how (and whether) they can
be more broadly applied into varied practice settings. We
evaluated the outcomes of CABG surgery in a network of
community hospitals affiliated in an active manner with
a major academic medical center. The absence of correla-
tion between surgical volume and outcome in such a small
sampling of hospitals was not surprising, especially given
the overall excellent results. However, what was compelling
is that within this same patient cohort, the association
between process measure and outcome was so strong.
Several points warrant discussion. First, the experience of
decreasing mortality for CABG surgery in response to
mandatory reporting has been somewhat universally
observed.16,17 Second, concerted quality improvement
efforts, assisted by well-organized clinical registries, has
proved successful in multiple settings in improving out-
comes.18-20 Third, although the application of process
measures in various areas of medicine has had variable
results in affecting outcomes, evidence is mounting that
the adherence to quality measures is associated with
improved mortality rates in CABG surgery, independent
of hospital or surgeon volume.21 However, what is notable
and somewhat unique in the present study is the correlation
of process measures with outcomes that are totally unre-
lated to the specific processes addressed. Evidence isery c February 2012
TABLE 5. Odds ratios of complications for patients with low- versus high-quality score
Variable
Unadjusted Adjusted for predicted score
OR (95% CI) P value ORs (95% CI) P value
Morbidity 1.79 (1.38–2.31) <.001
Stroke 1.60 (1.27–2.02) <.001 1.51 (1.18–1.93) .001
Reoperation 1.88 (1.44–2.46) <.001 1.65 (1.25–2.16) .003
Sternal infection 0.59 (0.03–10.89) .72 0.55 (0.03–11.03) .70
Prolonged ventilation 1.71 (1.34–2.19) <.001 1.54 (1.21–1.96) <.001
Renal failure 2.00 (1.07–3.75) .03 1.91 (1.09–3.35) .02
OR, Odds ratio; CI, confidence interval.
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on quality might be more important than specific protocols
in improving care.22 Each of these elements is prominent in
the HeartSource model—monitored review of all outcomes
in a risk-adjusted fashion using the highest standard of the
profession (the STS database and benchmarks), external
peer-review and open discussion of all deaths, significant
complications, and interesting and/or challenging cases,
shared protocols and educational opportunities, and empha-
sis on both process and outcome. It is not therefore surpris-
ing that surgical mortality has decreased with HeartSource
involvement in each of the three programs in the present
study that were not new programs.
The finding of an increased sternal wound infection
rate, even risk adjusted in the LV programs, despite its sta-
tistical significance, must be viewed with a certain amount
of caution, because only 6 patients in the entire study de-
veloped this complication. However, the greater rate of
stroke in the large-volume programs, even after risk ad-
justment, is somewhat difficult to explain, but has been
previously reported in a large study from the Nationwide
Inpatient Sample.23 It, therefore, warrants additional in-
vestigation. Likewise, increased adherence to the use of
the internal thoracic artery in larger programs was also
noted in a large patient group from the STS database7
and might represent a greater percentage of nonelective
cases in the LV centers.
Study Limitations
Although these results are certainly encouraging and sup-
portive of a paradigm of care that integrates the academic
medical center into the delivery of care at the community
hospital level, the present study had numerous limitations
that must be acknowledged. First, as a retrospective descrip-
tive study, the results must be seen as hypothesis-generating
rather than in any way definitive. The obvious absence of
any control group did not permit us to distinguish or prove
the specific causes for the results observed. The multifacto-
rial and somewhat unique nature of CABG surgery might
permit alternative explanations to those suggested.12 It re-
mains unknown whether the excellent results achieved in
our study could have been further improved by the addition
of volume to these programs. Case selection was notThe Journal of Thoracic and Camonitored, and a choice to focus on low-risk cases would
tend to make any differentiation in outcomes less apparent.
Moreover, the effect of surgeon recruitment cannot be
underestimated. In each case, the selection of surgeon was
made by demonstrated clinical excellence, maturity, and ap-
propriateness for academic appointment. It is therefore not
unlikely that the ‘‘practice makes perfect’’ phenomenon as
it relates to surgical experience was already ameliorated by
the selection of seasoned surgeons to direct the programs.
Second, the small sampling of five hospitals did not per-
mit definitive conclusions on a hospital level, although the
patient level datawere robust andwere analyzed in amanner
that accounted for clustering effects within centers. The po-
tential effect of statistical variance in LV measurements3
was ameliorated by using data frommultiple years. It is cer-
tainly notable, however, that two of the five hospitals had
less than the STS recommended threshold of 100 cases/
year in each of the years measured,24 and none of the centers
achieved the 450 Leapfrog benchmark in any year. Within
this context, that the more commonly invoked parameters
of hospital and surgeon volume25,26 had no relation to
mortality or overall morbidity, but that adherence to
quality measures did, is strongly suggestive that, at least
in this context, the latter parameter is considerably more
important in determining quality than the former.
Third, to evaluate a well-defined patient group with suffi-
cient data to drawmeaningful conclusions, our study only ex-
amined the results for CABG surgery. As has been previously
noted, CABG surgery, as a well-developed and frequently
performed procedure, might represent a unique case.12
Therefore, the applicability of these findings to valvular sur-
gery, or other areas of cardiac surgery, remains to be explored.
CONCLUSIONS
In the setting of a university-based community hospital
quality improvement program, excellent results can consis-
tently be obtained in CABG surgery in relatively LV pro-
grams. The surgical outcomes in this context are not
associated with program or surgeonvolume but directly cor-
relate with focus on quality as manifested by compliance
with evidence-based quality standards. A meaningful uni-
versity affiliation might represent a new quality paradigm
for cardiac surgery in the community hospital setting.rdiovascular Surgery c Volume 143, Number 2 291
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Dr Thoralf Sundt (Boston, Mass). Thanks, Paul, beautifully
presented, and I would like to say thanks for getting your slides
and your manuscript to me much earlier than I ever do for my
invited discussants.
It is an intriguing hypothesis and, I think, an important topic.
The volume/outcome issue seems to be a perennial topic, and it
was even raised yesterday here in this meeting. Strangely, multiple
studies have shown contradictory findings. It is much like the
on-pump coronary artery bypass report that we just finished
discussing, again a subject with many studies showing seemingly
exactly contrary results. The report yesterday regarding heart
transplantation suggested exactly the opposite of your work,
with higher volume associate with better outcomes.
I would have to say that my reading is that volume is not a good
surrogate for outcome. If we want to look at outcome, we ought to
look at outcome. I think we are all agreed that organizations such
as Leapfrog are looking under the wrong rock. If they want to look
at outcome, they ought to look at meaningful outcomes.
But I think you go beyond this point and address another issue
here—not just the question of whether or not volume is a good sur-
rogate, but a second question, which is implied in your hypothe-
sis—what does improve outcome, and, by inference, how can we
intervene to improve those outcomes beyond concentrating cases
in large-volume centers. It is a complex problem as it turns out.
This same debate is going on in the general surgical community
as they consider the introduction of the Surgical Care Improve-
ment Project (SCIP) measures and the correlation with surgical
site infections. The general surgeons are pulling their hair out, be-
cause they have seen a reduction in surgical site infections with the
introduction of the program, but when they now consider the effect
of each of the process variables one by one, they do not see good
correlation with the outcomes.
But I think that you have hit on the answer,which is simply that it
is the focus on process and the attention to outcome that is actually
important. I suspect that the participation in a process improvement
or quality-focused program amounts to ‘‘institutionalization’’ of
the ‘‘Hawthorn Effect’’—and, in fact, that might be a part of the ex-
planation for the volume effect—that high-volume centers have, of
necessity, improved process just by virtue of the actual quantity.
Although I agree with you up to this point, there are some issues
that I do not understand about your analysis. It is certainly possible
for an individual surgeon or system to focus on outcome, but not
actually hit the mark on all variables despite their best efforts.
What you have shown is that the patients in whom one meets the
process variables—process variables that have been shown to cor-
relate with good outcomes—have better outcomes. I could argue
that this is circular logic.ery c February 2012
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gates for a focus on quality measures? In other words, can we strat-
ify surgeons or institutions by their ‘‘batting average’’ in being
consistent with the quality outcomes? Presumably, those with
focus will hit the mark more often overall. Rather than looking
at high-volume surgeons and low-volume surgeons, can we look
at high-batting average surgeons and low-batting average surgeons
and then see how their patients do? You wound up tracking the in-
dividual patients to the adherence to the metrics. What about high-
compliance surgeons and low-compliance surgeons? So that is
question number one.
Number two, did you have any surgeons that operated in two
hospitals, two hospitals that might imply different systems factors
such as a different focus on quality? So, for example, a given sur-
geon in hospital A might have better or worse outcomes in hospital
B if the focus on quality at a systems level at that hospital is less.
Finally, what was the effect of the initiation of this program on
adherence to those quality measures? Did a given program demon-
strate better compliance with measures overall after joining the
program?
I would like to emphasize what might have gone past some of
the audience, because you went past it pretty quickly. This pro-
gram is not one that was developed to drive cases to Columbia
but one aimed at actually improving outcomes in the sites where
you have intervened. It is altruistic in that regard. Thus, I believe
that your work really answers the question that was posed during
the heart transplant presentation yesterday: how can we improve
quality in low-volume sites? Answer: Focus on quality.
Thanks. I really enjoyed your report very much.
Dr Kurlansky. Dr Sundt, thank you very much for your kind
comments. Unfortunately, the statistical necessity did not permit
us to effectively look at the hospital level or the surgeon level re-
garding their batting averages, because the models converge with
so few centers; only five centers and only 1 to 2 surgeons per cen-
ter. That is why we analyzed the data at the patient level. But it
would certainly be very instructive as time goes and we generate
more data to be able to track that.
We did not have any surgeons who operated at two hospitals in
this program. In fact, none of the surgeons in this program operated
at other hospitals. So we did not have access to try to assess that,
although there have been some interesting studies, reports in the
literature, regarding the effect of having, for example, a high-vol-
ume surgeon working in a low-volume program elsewhere and
whether their results correlated more with the low-volume centers
or the high-volume centers.
It is very difficult to be able to track exactly the effect of the pro-
gram, because at some of these centers we helped them start the
program. So there was not a program before. I can tell you this:The Journal of Thoracic and Cain those centers in which there was a program before, in every
case, we do know that the raw mortality declined. However, one
of the aspects of this program was the institution of an information
system that enabled us to track these sorts of results that did not
exist before. So I cannot even retrospectively go back and find
out what their performance measures were before we got there.
DrMarc Ruel (Ottawa, Ontario, Canada). Dear Paul, I greatly
enjoyed your presentation. I think, though, that there might be an
issue here in terms of the statistical power of the study. When you
are looking at dichotomous outcomes, power is not dependent on
the denominator but on the numerator (ie, the number of events).
For instance, with respect to mortality in your study, there were
roughly 20 events of the 2000 or so patients whom you studied.
So the power was fairly limited.
Therefore, I was wondering if you had the opportunity to calcu-
late what would be the power of your conclusions? For instance,
how certain are you and what power do you have to determine
that you would, for instance, have identified a 40% relative in-
crease in mortality in low-volume hospitals versus high-volume
hospitals? Were you able to get this information out of your data?
Thank you very much for a great talk.
Dr Kurlansky. You raise an incredibly important point as
pointed out yesterday so eloquently, that the absence of evidence
is not evidence of absence, the classic problem of type II errors.
And with only five centers, even with over 2000 patients, you
have to account for clustering within centers, and therefore the
power of this study to determine small differences or differences
in low event rates is very limited.
However, what I think is extremely important here is that in that
context where mortality and morbidity were not able to be distin-
guished, the power of compliance with National Quality Forum
measures was extremely well statistically correlated with the dif-
ference in outcome, which tells me that even if there was a differ-
ence that with larger numbers would be measurable between the
low-volume and the high-volume programs, that is not nearly as
powerful a predictor as the National Quality Forum focus on qual-
ity compliance. Also, I think that is probably consistent with what
was found with the review of the STS database that I alluded to
where there are over a million patients, and there was a statistical
correlation between outcome and volume, the degree to which
volume contributed to the variance in the overall quality score
was only 1%. So, although it might be a predictor or it might ac-
tually be involved and we were not able to see it with the limited
power of this study, I think that perhaps that limitation in power is
a benefit to this study, because the fact that we were able to see
some other parameter very powerfully highlights the point that
process is much more important than volume in determining
outcome.rdiovascular Surgery c Volume 143, Number 2 293
TABLE E1. Odds ratios of outcome measures in patients of low-
versus high-volume hospitals adjusted for predicted risk and
propensity for surgery in low- versus high-volume program
Variable OR (95% CI) P value
Mortality 1.06 (0.61–1.83) .84
Mortality or morbidity 1.09 (0.35–3.34) .88
Stroke 0.27 (0.15–0.46) <.001
Reoperation 1.04 (0.52–2.06) .92
Prolonged ventilation 1.11 (0.41–3.00) .83
Renal failure 1.12 (0.28–4.46) .87
Generalized estimating equation estimates for adjusted sternal infection analysis did
not converge owing to small number of infections. OR, Odds ratio; CI, confidence
interval.
TABLE E2. Odds ratios of outcome measures for patients with low-
versus high-volume surgeons adjusted for predicted risk scores
Variable OR (95% CI) P value
Mortality 1.60 (0.76–3.37) .22
Mortality or morbidity 1.13 (0.78–1.64) .51
Stroke 0.42 (0.14–1.29) .13
Reoperation 1.14 (0.60–2.19) .69
Sternal infection 0.66 (0.11–3.99) .65
Prolonged ventilation 1.10 (0.64–1.90) .73
Renal failure 0.96 (0.46–2.03) .92
OR, Oodds ratio; CI, confidence interval.
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